February 17, 2012
Novartis to revise product information in the European Union for high blood pressure drug Rasilez® following assessment by CHMP

February 13, 2012
FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers

February 07, 2012
Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease

February 01, 2012
FDA approves Novartis drug Glivec® label recommending extending treatment to three years for certain GIST patients after surgery

January 30, 2012
Novartis extends commitment to help achieve final elimination of leprosy

January 25, 2012
Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011

January 20, 2012
CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery

January 20, 2012
Novartis drug Signifor® recommended by CHMP for EU approval to treat patients with Cushing's disease

January 19, 2012
Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment

January 18, 2012
Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals